Skrubben bakom Nobelprisupptäckten

Det hör inte till vanligheterna att upptäckter som leder till Nobelpris görs på små biotechbolag. Ännu mer sällsynt är att arbetet bakom den prisbelönta forskni...

Mastering Urine Microscopy

On-demand Webinar: Microscopy in urinalysis.

High-performance Slide Scanner for Fluorescence, Brightfield and Polarization

ZEISS Axioscan 7 combines high speed digitization and outstanding image quality.

Advancing Drug Discovery by Combining Complex In-Vitro Models with AI-Powered 3D/4D Image Analysis

Free webinar organized by ZEISS.

Drug development booms in Medicon Valley

When it comes to developing new medicines, the Öresund region is one of the top performers in the EU. Companies working on commission for pharmaceutical compani...

Prövning av pillervaccin mot covid-19 avbryts i USA

Det amerikanska hälsodepartementet har beordrat stopp för en statligt finansierad fas IIb-studie som skulle utvärdera ett potentiellt pillervaccin mot covid-19.

Orbán's extended arm becomes health commissioner in the EU

Hungarian Olivér Várhelyi may soon become the most influential official for the healthcare and pharmaceutical industry in the EU. Várhelyi, who is close to Hung...

The new Swedish life science strategy – “It will consolidate Sweden as a leader”

Clinical trials and precision health are emphasised as key areas in the new national life science strategy.

In search of Marcel Proust's lost health

A great writer, but also a weak person and a hypochondriac. That has been the usual image of Marcel Proust. But the pediatrician and literary scholar Carl Lindg...

AZ gets approval for drug targeting rare disease – it may reduce cortisone dependence

AstraZeneca’s drug Fasenra gets an expanded indication in the EU and is now approved as a treatment for the rare autoimmune disease known as Churg-Strauss syndrome.

The Crucial Role of Core Imaging Facility Managers

User story from ZEISS and the University of York.

Medivir CEO on upcoming study: ”It's about working together with others”

Medivir is a small company with a big task: to take its drug candidate, via extensive clinical studies, all the way to a patient group that currently lacks appr...

KI-studie: Nässköljning kunde ge information om KOL

Förekomsten av ett visst protein i näsan kunde användas som underlag för bedömning av KOL, i en ny studie från forskare vid Karolinska institutet.

Mavatar AB

Are you curious about volume imaging for very large samples?

Exciting ZEISS Webinar!

A new life science cluster formed – “We are very strong in talent”

Stockholm and Uppsala’s joint life science cluster aims to be among the best in Europe. Pontus Holm, Life Science Coordinator for Region Stockholm, says the dec...

HAB Nicolai Johannsen

Investigations against AstraZeneca: ”Chinese interests may be behind them”

Why are there several investigations against AstraZeneca employees in China right now? Life Science Sweden continues to seek answers.

Lilly´s Nordic manager on Mounjaro launch in Sweden: "Patients deserve respect"

Another blockbuster diabetes and obesity drug has made its way into the Swedish market – with promises of a stable supply and availability for patients. “What w...

Amorfa material i centrum när Orexo tar fram nya formuleringar

Snabb upplösning, men med bibehållen stabilitet. Orexos nya drug delivery-plattform tar itu med problematiken hos amorfa material. "Vår teknologi har de positiv...

Roche’s Genentech terminates licencing deal with Norwegian biotech

Genentech is ending a license collaboration with Norwegian biotech Nykode Therapeutics regarding a clinical stage cancer vaccine program.

How to avoid measurement inaccuracies due to wear

Expert tip from ZEISS.

”The importance of stratification in a statistician’s August kitchen”

Ingrid Lönnstedt writes about an experiment of her own at home and about what lessons can be learned from it, in a science column.

MSD discontinues development of cancer drugs after trial failures

MSD suspends Phase 3 trials for two drug programs for different forms of cancer after trial failures.